| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypersensitivity | D006967 | 22 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Arterial Occlusive Diseases | D001157 | 12 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Leukemia, Erythroblastic, Acute | D004915 | 41 associated lipids |
| Vision Disorders | D014786 | 10 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Osteochondrodysplasias | D010009 | 3 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Hematologic Diseases | D006402 | 3 associated lipids |
| Muscular Dystrophies | D009136 | 10 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Hematuria | D006417 | 13 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
| Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
| Jain AB et al. | FK 506 dosage in human organ transplantation. | 1990 | Transplant. Proc. | pmid:1689890 |
| Demetris AJ et al. | Pathologic observations in human allograft recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689891 |
| Shapiro R et al. | The side effects of FK 506 in humans. | 1990 | Transplant. Proc. | pmid:1689892 |
| Van Thiel DH et al. | Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689893 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
| Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
| Thomson AW | FK-506 enters the clinic. | 1990 | Immunol. Today | pmid:1692221 |
| Saitoh Y et al. | Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. | 1990 | Jpn J Surg | pmid:1692892 |
| Rosen MK et al. | Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. | 1990 | Science | pmid:1693013 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
| Kurasawa K et al. | The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. | 1990 | Clin. Immunol. Immunopathol. | pmid:1698584 |
| Miyagawa J et al. | Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. | 1990 | Diabetologia | pmid:1698679 |
| Lagodzinski Z et al. | Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. | 1990 | Immunology | pmid:1698713 |
| Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
| Hara S et al. | The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. | 1990 | Clin. Immunol. Immunopathol. | pmid:1700936 |
| Murase N et al. | Effect of FK 506 on spontaneous diabetes in BB rats. | 1990 | Diabetes | pmid:1700959 |
| Kawashima H and Mochizuki M | Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. | 1990 | Exp. Eye Res. | pmid:1701148 |
| Siekierka JJ et al. | The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. | 1990 | J. Biol. Chem. | pmid:1701173 |
| Johansson A and Möller E | Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. | 1990 | Transplantation | pmid:1701570 |
| Reyes J et al. | Expressive dysphasia possibly related to FK506 in two liver transplant recipients. | 1990 | Transplantation | pmid:1701571 |
| Tsuji RF et al. | Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. | 1990 | J. Antibiot. | pmid:1701765 |
| Granelli-Piperno A et al. | The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. | 1990 | J. Exp. Med. | pmid:1701825 |
| Woo J et al. | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. | 1990 | Immunology | pmid:1703987 |
| Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
| McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Arai K et al. | Prolonged limb allograft survival with short-term treatment with FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468256 |
| Ishibashi M et al. | Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. | 1989 | Transplant. Proc. | pmid:2469228 |
| Starzl TE et al. | Liver transplantation: an unfinished product. | 1989 | Transplant. Proc. | pmid:2469232 |
| Hatanaka H et al. | FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. | 1989 | J. Antibiot. | pmid:2470720 |
| Gschwendt M et al. | The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. | 1989 | Immunobiology | pmid:2471685 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Tocci MJ et al. | The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. | 1989 | J. Immunol. | pmid:2472451 |
| Beck Y and Akiyama N | Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. | 1989 | Transplant. Proc. | pmid:2472695 |
| Thomson AW | FK-506--how much potential? | 1989 | Immunol. Today | pmid:2473767 |
| Ochiai T et al. | Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. | 1989 | Transplantation | pmid:2474208 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Leonard DK et al. | Toxicity of FK-506 in human fetal pancreas. | 1989 | Diabetes | pmid:2463195 |
| Stephen M et al. | Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. | 1989 | Transplantation | pmid:2463701 |